TABLE 2.

Characteristics of the Cas9 used in the different therapeutic approaches for FSHD.

Abbreviation	Species	PAM motif	Packaging size	Strategy	Reference
SpCas9	Streptococcus pyogenes	5’NGG-3′	∼ 4.2 kb	Double strand break	Himeda et al (2021); Joubert et al (2020); Goossens et al (2019)
				KRAB	Himeda et al (2021); Das et al (2021)
				ABE	Sikrova et al. (2021)
SaCas9	Staphylococcus aureus	5’-NNGRRT-3’.	∼ 3.2 kb	ABE	Sikrova et al (2021)
dSaCas9	Staphylococcus aureus	5′-NNGRRT-3′	∼ 3.2 kb	Epigenetic regulator	Himeda et al (2016)
CjCas9	Compylobocter jejuni	5′-NNNVRYM-3′	∼ 2.9 kb	ABE	Sikrova et al (2021)
NmCas9	Neisseria meningitidis	5′-NNNNGATT-3′	∼ 3.5 kb	Double strand break	Joubert et al (2020)

Packaging site include Cas9 and sgRNA together.

N=A/G/C/T; R=G/A; V=G/C/A; Y=C/T; M=A/C.

ABE, adenine base editor.